Evidence for Trisulfide Bonds in a Recombinant Variant of a Human IgG2 Monoclonal Antibody
- 10 July 2009
- journal article
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 81 (15), 6148-6155
- https://doi.org/10.1021/ac9006254
Abstract
The hinge region of human IgG2 contains four cysteine residues involved in disulfide linkages between the heavy chains, as well as the heavy and light chains. These linkages provide the fundamental framework of three distinct IgG2 disulfide isoforms recently described. Here, we detail another, disulfide-related post-translational modification in a recombinant variant of human IgG2. Heterogeneity associated with this antibody was separated into several fractions by anion-exchange chromatography (AEX), which is an important initial step that highlights the resolving power of surface charge-based HPLC techniques. Mass spectrometry of the intact antibody revealed weakly resolved discrete covalent additions of 25−35 Da in one of the two main AEX fractions. Digestion by endoproteinase Lys-C performed under nonreducing conditions, as well as tandem MS experiments, narrowed the modification to the peptide-containing disulfide-bridged hinge structure. High mass resolution and accuracy measurements of the peptide strongly suggested an addition of one or two S atoms. The modification could be eliminated by a mild reducing treatment of the intact antibody. Overall, these findings are consistent with the replacement of up to two disulfide bridges (S−S) with a like number of trisulfides (S−S−S) in the antibody hinge. The trisulfide modification is rather uncommon for proteins and its possible origins in the IgG2 variant are discussed.Keywords
This publication has 36 references indexed in Scilit:
- Antibodies for the treatment of bacterial infections: current experience and future prospectsCurrent Opinion in Biotechnology, 2008
- Implementation of advanced technologies in commercial monoclonal antibody productionBiotechnology Journal, 2008
- Mass spectrometry for structural characterization of therapeutic antibodiesMass Spectrometry Reviews, 2008
- Bioseparation in Antibody Manufacturing: The Good, The Bad and The UglyBiotechnology Progress, 2008
- Recombinant Antibodies as Therapeutic AgentsBioDrugs, 2008
- Antibody engineering and modification technologiesBiomolecular Engineering, 2007
- Process analytics for purification of monoclonal antibodiesJournal of Chromatography B, 2007
- Scale-up of monoclonal antibody purification processesJournal of Chromatography B, 2007
- Antibody productionAdvanced Drug Delivery Reviews, 2006
- Therapeutic antibodies for human diseases at the dawn of the twenty-first centuryNature Reviews Drug Discovery, 2003